Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Patent
1990-03-19
1992-06-09
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
514168, 552653, A61K 3159, C07J 900
Patent
active
051207222
ABSTRACT:
The compounds 1.alpha.,25(S), 26-trihydroxy-.DELTA..sup.22 -cholecalciferol; 1.alpha.,25(R), 26-trihydroxy-.DELTA..sup.22 -cholecalciferol; 1.alpha.,25(S),26-trihydroxyergocalciferol, 1.alpha.,25(R),26-trihydroxyergocalciferol and pharmaceutical compositions comprising the compounds as well as methods of making and using these compounds are disclosed.
REFERENCES:
patent: 3741996 (1973-06-01), DeLuca et al.
patent: 3880894 (1975-04-01), DeLuca et al.
patent: 3907843 (1975-09-01), DeLuca et al.
patent: 4022768 (1977-05-01), Matsynaga et al.
patent: 4225596 (1980-09-01), DeLuca et al.
patent: 4391802 (1983-07-01), Suda et al.
patent: 4407754 (1983-10-01), Barner et al.
patent: 4448721 (1984-05-01), DeLuca et al.
patent: 4588528 (1986-05-01), DeLuca et al.
patent: 4617297 (1986-10-01), Boris
patent: 4728643 (1984-11-01), Holick et al.
Windholz et al., "The Merck Index", Merck Co. 9th Ed. p. 1289 (1979).
Frampton, et al., Inhibition of Human Cancer Cell Growth by 1,25-Dihydroxy-vitamin D.sub.3 Metabolites, Cancer Research 43:4443,4447, 1983.
K. Schaefer, D. Von Herrath, "Vitamin D 1980--Eine Bestandsaufnahme".
Dokoh, et al., The Ovary: A Target Organ for 1,25-Dihydroxyvitamin D.sub.3, Endocrinology 112: 200-206, 1983.
Reitsma, et al., Vitamin D.sub.3 Regulates C-myc Oncogene Expression in HL-60 Leukemic Cells, J. Cell. Biol. 97(5):347a, 1983.
Murao, et al., Control of Macrophage Cell Differentiation in Human Promyelocytic HL-60 Leukemia Cells by 1,25-Dihydroxyvitamin D.sub.3 and Phorbol-12-myristate-13-acetate, Cancer Research 43(8): 4989-4996, 1983.
Rigby, et al., 1,25-Dihydroxyvitamin D.sub.3 Induces Granulocytic Differentiation and Myeloid Specific Antigens in the HL-60 Promyelocytic Leukemia Cell Line, Blood 62(5): 153a, 1983.
Shuna, et al., Biological Activity of 24,24-Difluoro-1.alpha.,25-Dihydroxyvitamin D.sub.3 -26,23 Lactone in Inducing Differentiation of Human Myeloid Leukemia Cells, Arch. Biochem. Biophys,220: 90-94, 1983.
Abe et al., Differentiation of Mouse Myeloid Leukemia Cells Induced by 1.alpha.,25-Dihydroxyvitamin D.sub.3 ; Proc. Natl. Acad. Sci.; U.S.A. 78:4990-4994, 1981.
McCarthy et al., 1.alpha.,25-Dihydroxyvitamin D.sub.3 Causes Granulocytes From Patients with Chronic Granylocytic Leukemia to Differentiate Into Myoctye-Macrophages, Exp. Hematol. 11(Suppl. 14):200, 1983.
Honma et al., 1.alpha.,25-Dihydroxyvitamin D.sub.3 and 1.alpha.-hydroxyvitamin D.sub.3 Prolong Survival Time of Mice Inoculated with Myeloid Leukemia Cells, Cell Biology, 80:201-204, 1983.
Kasukabe, et al., Control of Proliferating Potential of Myeloid Leukemia Cells During Long Term Treatment with Vitamin D.sub.3 Analogues and Other Differentiation Inducers in Combination with AntiLeukemic Drugs, Cancer Res. 47(6):567-572, 1987.
Olsson et al., Induction of Differentiation of the Human Histocytic Lymphoma Cell Line U-937 by 1.alpha.,25-Dihydroxycholecalciferol, Cancer Research 43(12),5862-5867, 1983.
Eisman, et al., 1,25-Dihydroxyvitamin D Receptor in Breast Cancer Cells, Lancet, Dec. 22/29: 1335-1336, 1979.
Frampton, et al., Presence of 1,25-Dihdyroxyvitamin D.sub.3 Receptors in Established Human Cancer Cell Lines in Culture, Cancer Research 42: 1116-1119, 1982.
Colston et al., 1,25-Dihdyroxyvitamin D.sub.3 Receptors in Human Epithelial Cancer Cell Lines, Cancer Research 42: 856-859, 1982.
Sher et al., Whole Cell Uptake and Nuclear Localization of 1,25-Dihydroxycholecalciferol by Breast Cancer Cells in Culture, Biochem. J. 200:315-320, 1981.
Sato et al., Antitumor Effect of 1.alpha.,-Hydroxyvitamin D.sub.3, Tohoku, J. Exp. Med., 138:445-446, 1982.
McCarthy et al., A Role for 1,25-Dihydroxyvitamin D.sub.3 in Control of Bone Marrow Collagen Deposition? Lancet, Jan. 14: 78-80, 1984.
Eisman et al., Suppression of In Vivo Growth of Human Cancer Solid Tumor Xenografts, by 1,25-Dihydroxyvitamin D.sub.3, Cancer Res. 47: 21-25, 1987.
Baggiolini Enrico G.
Batcho Andrew D.
Truitt Gary A.
Uskokovic Milan R.
Wovkulich Peter M.
Chang Celia
Ciambrone Coletti Ellen
Gould George M.
Hoffmann-La Roche Inc.
Isgro William S.
LandOfFree
Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for tre does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for tre, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for tre will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1804594